AxoGen Inc. (AXGN)

40.00
0.25 0.62
NASDAQ : Health Technology
Prev Close 40.25
Open 40.05
Day Low/High 40.00 / 41.73
52 Wk Low/High 11.30 / 41.00
Volume 411.29K
Avg Volume 318.90K
Exchange NASDAQ
Shares Outstanding 34.56M
Market Cap 1.34B
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting AXGN Put And Call Options For February 16th

Interesting AXGN Put And Call Options For February 16th

Investors in AxoGen Inc saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AXGN options chain for the new February 16th contracts and identified one put and one call contract of particular interest.

AXGN Crosses Above Average Analyst Target

AXGN Crosses Above Average Analyst Target

In recent trading, shares of AxoGen Inc have crossed above the average analyst 12-month target price of $31.00, changing hands for $31.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AxoGen To Participate At AAHS ASPN ASRM 2018 Annual Meetings

AxoGen To Participate At AAHS ASPN ASRM 2018 Annual Meetings

Several presentations will highlight the growing body of clinical evidence supporting the company's platform for nerve repair

AxoGen Corporation Announces Avance® Nerve Graft Recipient Selected To Ride On Donate Life Rose Parade® Float

AxoGen Corporation Announces Avance® Nerve Graft Recipient Selected To Ride On Donate Life Rose Parade® Float

Parade float will highlight the life-changing power of tissue and organ donation

First Week of July 2018 Options Trading For AxoGen (AXGN)

First Week of July 2018 Options Trading For AxoGen (AXGN)

Investors in AxoGen Inc saw new options begin trading this week, for the July 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AxoGen, Inc. Reports 2017 Third Quarter Financial Results

AxoGen, Inc. Reports 2017 Third Quarter Financial Results

Record Q3 Revenue of $16.0 million, representing 43% growth over prior year

AxoGen, Inc. Receives David J. Gury Company Of The Year Award From BioFlorida

AxoGen, Inc. Receives David J. Gury Company Of The Year Award From BioFlorida

Award recognizes company's contribution to Florida's life sciences industry

AxoGen To Participate At 99th Annual American Association Of Oral And Maxillofacial Surgeons Meeting

AxoGen To Participate At 99th Annual American Association Of Oral And Maxillofacial Surgeons Meeting

AxoGen offers Oral and Maxillofacial surgeons solutions for the repair of peripheral nerve damage

AXGN Crosses Above Average Analyst Target

AXGN Crosses Above Average Analyst Target

In recent trading, shares of AxoGen Inc have crossed above the average analyst 12-month target price of $16.15, changing hands for $16.35/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AxoGen To Participate At 72nd Annual American Society For Surgery Of The Hand Meeting

AxoGen To Participate At 72nd Annual American Society For Surgery Of The Hand Meeting

Growing body of data related to repair of mixed, motor, and long-gap nerve injuries will be reviewed at hosted symposium

AxoGen, Inc. Reports 2017 Second Quarter Financial Results

AxoGen, Inc. Reports 2017 Second Quarter Financial Results

Record Q2 Revenue of $15.2 million, representing 46% growth over prior year